Improved Liver Function in Patients with Liver Cirrhosis After Autologous Bone Marrow Cell Infusion Therapy

  title={Improved Liver Function in Patients with Liver Cirrhosis After Autologous Bone Marrow Cell Infusion Therapy},
  author={Shuji Terai and Tsuyoshi Ishikawa and Kaoru Omori and Koji Aoyama and Yoshio Marumoto and Yohei Urata and Yuichirou Yokoyama and Koichi Uchida and Takahiro Yamasaki and Yasuhiko Fujii and Kiwamu Okita and Isao Sakaida},
  journal={STEM CELLS},
We here report nine liver cirrhosis (LC) patients that underwent autologous bone marrow cell infusion (ABMI) from the peripheral vein. Subjects were patients with LC with total bilirubin of less than 3.0 mg/dl, platelet count of more than 5 (1010/l), and no viable hepatocellular carcinoma on diagnostic imaging. Autologous bone marrow (BM; 400 ml) was isolated from the ilium under general anesthesia. Mononuclear cells (MNCs) were separated by cell washing and were infused via the peripheral vein… 

Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients

  • S. TeraiI. Sakaida
  • Medicine, Biology
    Hepatology research : the official journal of the Japan Society of Hepatology
  • 2008
ABMI therapy should be considered as a novel treatment for LC patients according to translational research on the development of cell therapy using autologous bone marrow cell for liver cirrhosis patients.

Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis

Although clinical improvement was sustained for more than 6 months, histological changes in the liver returned to baseline 6 months after ABMI, further comparative studies are warranted.

Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis.

BM-MNCs transplantation is safe and effective in patients with decompensated liver cirrhosis and it also decreases the incidence of serious complications, as well as serious complications such as hepatic encephalopathy and spontaneous bacterial peritonitis.

CLINICAL TRIALS STUDY Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis

Liver function parameters were improved one month after BM-MNCs transfusion in cirrhosis patients, followed by albumin level, total bilirubin, prothrombin time, pro Thrombin activity, fibrinogen and platelet count, and the efficacy of BM- MNCs transplantation lasted 3-12 mo as compared with the control group.

Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis.

ABMi for patients with ALC helps improve liver function parameters in comparison with observation during abstinence and ameliorates the degree of fibrosis in terms of serum markers and bone marrow activation in most cases.

Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells.

A proof-of-concept showing that infusion of bone marrow cells (BMCs) improved liver fibrosis and sequentially activated proliferation of hepatic progenitor cells and hepatocytes, further promoting restoration of liver functions is developed.

Autologous Bone Marrow Mononuclear Cell Transplantation in Patients with Decompensated Alcoholic Liver Disease: A Randomized Controlled Trial

Autologous BMMCT, compared to SMT is a safe procedure but did not result in an expanded HPC compartment or improved liver function, suggesting either insufficient regenerative stimulation after BMM CT or resistance to liver regenerative drive in patients with decompensated alcoholic cirrhosis.

Mesenchymal Bone Marrow-derived Stem Cells Transplantation in Patients with HCV Related Liver Cirrhosis

Intraparenchymal transplantation of autologous BMSCs improved the functional condition of the liver, stimulated reparative processes in hepatocytes, and decreased extracellular matrix protein (EMP) count in hepatic tissues of patients with LC.

Autologous Infusion of Expanded Mobilized Adult Bone Marrow-Derived CD34+ Cells Into Patients With Alcoholic Liver Cirrhosis

It is safe to mobilize, expand, and reinfuse autologous CD34+ cells in patients with ALC and the clinical and biochemical improvement in the study group is encouraging and warrants further clinical trials.



Liver from bone marrow in humans

It is shown that in humans, hepatocytes and cholangiocytes can be derived from extrahepatic circulating stem cells, probably of bone marrow origin, and such “transdifferentiation” can replenish large numbers of hepatic parenchymal cells.

Portal Application of Autologous CD133+ Bone Marrow Cells to the Liver: A Novel Concept to Support Hepatic Regeneration

Early experience with portovenous application of autologous CD133+ BMSCs could suggest that this novel therapeutic approach bears the potential of enhancing and accelerating hepatic regeneration in a clinical setting.

Lesson from the GFP/CCl4 model--translational research project: the development of cell therapy using autologous bone marrow cells in patients with liver cirrhosis.

Results from the GFP/CCl(4) model showed that cell therapy using autologous bone marrow cells has the potential to become an effective treatment for patients with liver failure.

Serum hepatocyte growth factor levels in primary biliary cirrhosis

Serum HGF levels in almost all patients with primary biliary cirrhosis were within normal limits despite increased hepatocyte proliferation, supporting the hypothesis that HGF serum levels may reflect liver dysfunction rather than active hepatocytes proliferation.

An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes.

The present study found that persistent injury induces efficient trans-differentiation of BMCs into functional hepatocytes through immature hepatoblasts in mice with liver cirrhosis induced by carbon tetrachloride, revealing that recipient conditions and microenvironments represent key factors for successful cell therapy using BMCs.

Rapid and automated processing of bone marrow grafts without Ficoll density gradient for transplantation of cryopreserved autologous or ABO-incompatible allogeneic bone marrow.

This paper describes the experience with a rapid automated method for the isolation of mononuclear cells (MNC) from large volumes of bone marrow using a Fenwal CS-3000 cell separator without employing density gradient materials.

Characterization and Clinical Application of Human CD34+ Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colony‐Stimulating Factor

Evidence that the CD34+ cell population in granulocyte colony‐stimulating factor‐mobilized blood contains cells with the potential to form hepatocyte‐like cells is supported, and G‐CSF was given to five patients with liver insufficiency to mobilize their stem cells for collection by leukapheresis.

Detection of proliferating hepatocytes by immunohistochemical staining for proliferating cell nuclear antigen (PCNA) in patients with acute hepatic failure.

Results show that liver regeneration could take place after massive necrosis of liver cells in survivors from acute hepatic failure and that immunohistochemical staining for PCNA is useful for prognostic evaluation.